The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Genentech (Inst); Novartis (Inst)
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).
 
Amer Methqal Zeidan
Honoraria - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; Epizyme; Geron; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Epizyme; Geron; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Trovagene
 
Leyla Hernandez Donoso
Employment - Novartis
 
Sejla Hodzic
Employment - Novartis
 
Henry F Owusu
Employment - Novartis
 
Dhrubajyoti Pathak
Employment - Novartis
 
Summera Qiheng Zhou
No Relationships to Disclose
 
Eytan Stein
Stock and Other Ownership Interests - Auron Therapeutics
Consulting or Advisory Role - Abbvie; Agios; Aptose Biosciences; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Calithera Biosciences; CTI BioPharma Corp; Daiichi Sankyo; Debiopharm Group; Foghorn Therapeutics; GEMoaB; Genentech; Genesis Pharma; Gilead Sciences; Immunogen; Janssen; Jazz Pharmaceuticals; Jnana Therapeutics; Menarini; Neoleukin Therapeutics; Novartis; OnCusp Therapeutics; Ono Pharmaceutical; PinotBio; SERVIER; Syndax
Research Funding - agios (Inst); Bayer (Inst); BioTheryX (Inst); Bristol-Myers Squibb/Celgene (Inst); Cleave Biosciences (Inst); Eisai (Inst); Foghorn Therapeutics (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); Prelude Therapeutics (Inst); SERVIER (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst)